Cogent Biosciences Inc(COGT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.44 | Insider Own | 10.22% | Shs Outstand | 171.6M | Perf Week | 2.46% |
| Market Cap | 5.55B | Forward P/E | - | EPS next Y | 50.78% | Insider Trans | -0.26% | Shs Float | 155.8M | Perf Month | 0.47% |
| Enterprise Value | 5.07B | PEG | - | EPS next Q | -0.56 | Inst Own | 103.24% | Short Float | 12.62% | Perf Quarter | -19.11% |
| Income | -0.38B | P/S | - | EPS this Y | -2.59% | Inst Trans | 3.61% | Short Ratio | 10.02 | Perf Half Y | -11.92% |
| Sales | 0.00B | P/B | 11.75 | EPS next 5Y | - | ROA | -68% | Short Interest | 19.66M | Perf YTD | -9.88% |
| Book/sh | 2.72 | P/C | 7.01 | EPS past 3/5Y | -2.22% 30.89% | ROE | -109.74% | 52W High | -26.8% ($43.73) | Perf Year | 97.59% |
| Cash/sh | 4.57 | P/FCF | - | Sales past 3/5Y | - | ROIC | -48.66% | 52W Low | 132.29% ($13.78) | Perf 3Y | 288.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 4.92% | Gross Margin | - | Volatility(W/M) | 3.42% 4.01% | Perf 5Y | 292.28% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.57 | EPS Q/Q | 12.21% | Profit Margin | - | RSI (14) | 54.59 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.57 | Sales Q/Q | - | SMA20 | 4.9% ($30.51) | Beta | 0.35 | Target Price | $55.82 |
| Payout | - | Debt/Eq | 0.46 | Earnings | 2026/8/10 | SMA50 | -2.15% ($32.71) | Rel Volume | 0.91 | Prev Close | $30.91 |
| Employees | 258 | LT Debt/Eq | 0.46 | EPS/Sales Surpr. | 3.06% - | SMA200 | -10.51% ($35.77) | Avg Volume(3M) | 1.96M | Price | $32.01 |
| IPO | 2018/3/29 | Option/Short | Yes/Yes | Trades | 14188 | Volume | 1,778,844 | Change | 3.56% |
A late-stage clinical biotech company developing therapies that target specific genetic mutations. It is advancing targeted treatment candidates in late-stage clinical trials for rare blood disorders and select cancers, making it a biotech healthcare stock whose price is driven by clinical results, regulatory filings, and funding conditions for its lead candidates.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded about as much as usual. That is 91% of its average volume.
COGT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -2.6% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +292.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #49 of 594 in the industry
Based on market cap of $6B.
KOD#46 Kodiak Sciences Inc $6B PER - 
CGON#47 Cg Oncology Inc $6B PER - 
MIRM#48 Mirum Pharmaceuticals Inc $6B PER - COGT#49 Cogent Biosciences Inc $6B PER - 
ERAS#50 Erasca Inc $5B PER - 
FAQ
What kind of company is COGT?
COGT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of COGT?
The market cap of COGT is approximately $5.6B, ranking 1,296 within its sector.
What is the 52-week high and low for COGT?
COGT has recorded a 52-week high of $43.73 and a low of $13.78.
